标题
Guideline for the treatment of chronic lymphocytic leukaemia
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume 182, Issue 3, Pages 344-359
出版商
Wiley
发表日期
2018-07-16
DOI
10.1111/bjh.15460
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study
- (2018) Anne-Sophie Michallet et al. HAEMATOLOGICA
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study
- (2018) Anne-Sophie Michallet et al. HAEMATOLOGICA
- Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
- (2017) Iris de Weerdt et al. HAEMATOLOGICA
- NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017
- (2017) William G. Wierda et al. Journal of the National Comprehensive Cancer Network
- Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies
- (2017) J. J. Shatzel et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL
- (2017) T Munir et al. LEUKEMIA
- Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL
- (2017) D R Howard et al. LEUKEMIA
- Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL
- (2017) Niamh Appleby et al. LEUKEMIA & LYMPHOMA
- Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
- (2017) M Montillo et al. Blood Cancer Journal
- Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
- (2017) Iris de Weerdt et al. HAEMATOLOGICA
- Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Asher A Chanan-Khan et al. Lancet Haematology
- Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
- (2017) Jeffrey A Jones et al. Lancet Haematology
- The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: A study of 180 consecutive patients
- (2017) C. S. Tam et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
- (2016) Mohamed A. Kharfan-Dabaja et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia
- (2016) F. Nadeu et al. BLOOD
- Idelalisib in the management of lymphoma
- (2016) C. Y. Cheah et al. BLOOD
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
- (2016) A. R. Mato et al. BLOOD
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
- (2016) Susan O'Brien et al. LANCET ONCOLOGY
- Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
- (2016) Asher Chanan-Khan et al. LANCET ONCOLOGY
- Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy
- (2016) Stefano Molica et al. LEUKEMIA RESEARCH
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial
- (2016) Richard Greil et al. Lancet Haematology
- Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience
- (2015) Luc-Matthieu Fornecker et al. AMERICAN JOURNAL OF HEMATOLOGY
- Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
- (2015) D. Rossi et al. BLOOD
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
- (2015) P. A. Thompson et al. BLOOD
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- (2015) K. Fischer et al. BLOOD
- Poor functional antibody responses are present in nearly all patients with chronic lymphocytic leukaemia, irrespective of total IgG concentration, and are associated with increased risk of infection
- (2015) Helen M. Parry et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update
- (2015) Jessica P. Hwang et al. JOURNAL OF CLINICAL ONCOLOGY
- Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
- (2015) Peter Hillmen et al. LANCET
- Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
- (2015) Marinus H J van Oers et al. LANCET ONCOLOGY
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
- (2015) Mohammed Z H Farooqui et al. LANCET ONCOLOGY
- Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia
- (2015) K A Rogers et al. LEUKEMIA
- Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997
- (2015) David M. Lucas et al. LEUKEMIA & LYMPHOMA
- Management of adverse events associated with idelalisib treatment: expert panel opinion
- (2015) Steven E. Coutré et al. LEUKEMIA & LYMPHOMA
- Mutations driving CLL and their evolution in progression and relapse
- (2015) Dan A. Landau et al. NATURE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia?
- (2015) Peter Dreger et al. Current Hematologic Malignancy Reports
- Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody
- (2015) Valentin Goede et al. Oncology Research and Treatment
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
- (2015) Kami J. Maddocks et al. JAMA Oncology
- Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab
- (2014) Ricardo García Muñoz et al. ANNALS OF HEMATOLOGY
- Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
- (2014) C. S. Tam et al. BLOOD
- Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib
- (2014) D. Wodarz et al. BLOOD
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
- (2014) P. Dreger et al. BLOOD
- Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia
- (2014) Marietta S. Truger et al. BRITISH JOURNAL OF HAEMATOLOGY
- A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch
- (2014) Farrukh T. Awan et al. BRITISH JOURNAL OF HAEMATOLOGY
- U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
- (2014) H.-Z. Lee et al. CLINICAL CANCER RESEARCH
- Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials
- (2014) V. Goede et al. HAEMATOLOGICA
- Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model
- (2014) T. Baumann et al. HAEMATOLOGICA
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia
- (2013) Norbert Niederle et al. ANNALS OF HEMATOLOGY
- Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
- (2013) P. Abrisqueta et al. BLOOD
- 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
- (2013) Lorry G. Rubin et al. CLINICAL INFECTIOUS DISEASES
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- First immunochemotherapy outcomes in elderly patients with CLL: A retrospective analysis
- (2013) Anne-Sophie Michallet et al. Journal of Geriatric Oncology
- Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
- Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
- (2011) X. C. Badoux et al. BLOOD
- Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment
- (2011) Kate Hodgson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hematologist/oncologist disease-specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
- (2011) Tait D. Shanafelt et al. CANCER
- Optimal Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia
- (2011) Valentin Goede et al. DRUGS & AGING
- Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2011) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches
- (2010) Vicki A. Morrison BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia
- (2010) Franz Josef Gassner et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
- (2010) Tadeusz Robak et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia
- (2009) Matthew Kaufman et al. LEUKEMIA & LYMPHOMA
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma
- (2008) Clive S. Zent et al. BRITISH JOURNAL OF HAEMATOLOGY
- Molecular diagnostics in chronic lymphocytic leukemia – Pathogenetic and clinical implications
- (2008) Thorsten Zenz et al. LEUKEMIA & LYMPHOMA
- Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia
- (2008) Paul Thurmes et al. LEUKEMIA & LYMPHOMA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now